Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

•Optimal dosing interval of bone-targeting agents (BTAs) has not been fully defined.•Study of 4 vs 12-weekly BTAs in breast or prostate cancer pts with bone metastases.•Study arms showed no significant differences SSE rates, time to SSEs or toxicity.•There were however significant differences in cost-effectiveness results.•On study SSE (12-weekly arm) associated with slight increase in subsequent SSEs.